Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Regulatory Update – GSK announces submissions in the EU & US for new indications for Promacta®/Revolade®
GSK's submitted regulatory applications in the EU and US related to eltrombopag to increase platelet counts in patients with chronic hep C
-
GSK secures future of local playing fields with Fields in Trust as part of London 2012 legacy
GSK entered a partnership with FIT to secure the future of its Swyncombe Avenue Playing Fields, where hundreds of local people enjoy sport
-
GSK announces start of Phase III programme for combination of dabrafenib (GSK2118436) and trametinib (GSK1120212) in BRAF V600 mutation-positive metastatic cutaneous melanoma
The start of a Phase III programme evaluating the combination of dabrafenib, its BRAF inhibitor, and trametinib, its MEK inhibitor,
-
GlaxoSmithKline confirms US District Court ruling in Pronova BioPharma’s favour on Lovaza™ patents
GSK which has the marketing rights for Lovaza in the US and Puerto Rico, confirmed that U.S. District Judge Sue Lewis Robinson...
-
GSK receives positive opinion from European CHMP for pazopanib in the treatment of patients with certain advanced soft tissue sarcomas
GSK announced that the EMA CHMP has issued a positive opinion recommending marketing authorisation for Votrient for the treatment of STS.
-
Innovative public-private collaboration launches to tackle antibiotic research
GSK & AZN launch a pioneering approach to antibiotic research in Europe and address key barriers to the development of antibiotics.
-
Two overall winners announced at prestigious national award ceremony in London’s Science Museum
For the first time in its 15 year history the judges of the GSK IMPACT Awards could not choose one winner so instead awarded two prizes.
-
GSK statement on tender offer to acquire Human Genome Sciences
GSK commented on HGS Board of Directors decision to recommend against GSK's offer to acquire all outstanding shares of HGS for US$13.00
-
GlaxoSmithKline completes transaction to increase its ownership in Theravance
Approval by Theravance, Inc. stockholders at their Annual Meeting, GSKs acquisition of 10M shares of Theravance common stock has completed.
-
GlaxoSmithKline to fully acquire Cellzome for £61 million
GSK announced it has entered into an agreement to acquire shares in Cellzome, leader in the development of proteomics technologies for $99m
-
GSK statement on BBC Panorama broadcast: ‘the truth about tax’
GSK issued the following statement in response to the BBC Panorama programme related to Corporation Tax payments in the UK and Luxembourg
-
Stiefel receives US FDA approval of Fabior™ Foam, 0.1%
Stiefel, a GSK company, announced that the FDA has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%.
-
GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
GSK commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences for US$13.00 per share
-
GSK to commence tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
GSK announced it won't participate in Human Genome Sciences strategic alternatives review process
-
James Shannon named GlaxoSmithKline Chief Medical Officer
James Shannon has been named GSK's Chief Medical Officer (CMO), effective 1/05, accountable for medical governance & patient safety
-
GlaxoSmithKline plc appoints two Non-Executive Directors to its Board
GSK announces that Ms. Lynn Elsenhans and Ms. Jing Ulrich will join Board with effect from 1 July 2012 as Non-Executive Directors.
-
GlaxoSmithKline and Yale University establish drug discovery collaboration to design potential new class of medicines
GSK and Yale established a drug discovery research collab to design a potential class of medicines that degrade disease-causing proteins.
-
GlaxoSmithKline receives European authorisation for Nimenrix™ (Meningococcal group A, C, W-135 and Y conjugate vaccine)
GSK announced today that the EC has granted marketing authorisation for Nimenrix for immunisation against invasive meningococcal disease
-
GSK and University of Nottingham collaborate to create Centre of Excellence for sustainable chemistry
GSK & University of Nottingham formalised a collaboration to establish a new laboratory to accommodate the Centre of Excellence
-
Children in Ghana to be vaccinated against diarrhoeal disease with the introduction of GSK’s Rotarix™ vaccine
GSK welcomes GAVI announcement that rotavirus vaccine, Rotarix, will be introduced into national vaccination programme in Ghana.
